Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a clinical-stage biotechnology company advancing a pipeline of oral small molecule degrader medicines based on targeted protein degradation (TPD). This news page aggregates company announcements, clinical updates, collaboration developments and capital markets activity related to Kymera’s work in immunological and other serious diseases.
Readers can follow detailed updates on KT-621, Kymera’s investigational first-in-class oral STAT6 degrader in Phase 2 clinical testing for Type 2 inflammatory diseases such as atopic dermatitis and asthma. News items include Phase 1b and Phase 2 trial progress, biomarker and clinical endpoint data, and regulatory milestones such as U.S. FDA Fast Track designation for moderate to severe atopic dermatitis. Coverage also extends to KT-579, an investigational oral IRF5 degrader for immune-mediated conditions, as it moves from preclinical work toward first-in-human studies.
In addition to internal programs, this feed highlights updates on Kymera’s partnered assets, including the IRAK4 degrader KT-485/SAR447971 in collaboration with Sanofi for immuno-inflammatory diseases and the oral CDK2 molecular glue degrader program with Gilead Sciences for potential use in breast cancer and other solid tumors. Investors can also find information on public offerings of common stock, shelf registration statements, and other corporate events disclosed through press releases and SEC filings.
By reviewing Kymera news on this page, users can track clinical trial milestones, regulatory interactions, collaboration announcements and financing transactions that shape the company’s development trajectory. For those researching KYMR stock or the evolution of targeted protein degradation in immunology and oncology, this consolidated news view provides ongoing context around Kymera’s pipeline and corporate strategy.
Kymera Therapeutics (NASDAQ: KYMR) outlined 2026 objectives to advance its oral immunology portfolio, highlighting clinical and preclinical milestones for STAT6 degrader KT-621 and IRF5 degrader KT-579.
Key points: KT-621 BROADEN2 Phase 2b in atopic dermatitis (enrollment complete in 2026; data mid-2027), BREADTH Phase 2b in eosinophilic asthma initiated (data late-2027), and FDA Fast Track in AD (Dec 2025). KT-579 Phase 1 healthy volunteer trial to start in 1Q26 with data in 2H26. Company reports $1.6 billion cash runway into 2029 and plans to advance at least one new development candidate toward IND in 2026.
Kymera Therapeutics (NASDAQ: KYMR) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 9:00 a.m. PT / 12:00 p.m. ET. Nello Mainolfi, PhD, Founder, President and CEO, will review Kymera’s clinical progress and anticipated 2026 milestones.
A live webcast of the presentation and Q&A will be available under “News and Events” in the Investors section of the company website at www.kymeratx.com, with a replay and archived presentation available after the event.
Kymera Therapeutics (NASDAQ: KYMR) closed an upsized underwritten public offering on Dec 11, 2025, selling 8,050,000 shares of common stock at a public offering price of $86.00 per share, which included 1,050,000 shares from the full exercise of the underwriters’ option.
The press release reports gross proceeds of approximately $692.3 million before deducting underwriting discounts, commissions and estimated offering expenses. The offering was conducted under an automatically effective Form S-3 registration and a final prospectus supplement filed with the SEC.
Kymera Therapeutics (NASDAQ: KYMR) announced that the U.S. FDA granted Fast Track designation to KT-621, a first-in-class oral STAT6 degrader for moderate to severe atopic dermatitis (AD), on December 11, 2025.
Fast Track follows positive BroADen Phase 1b AD results showing STAT6 degradation, biomarker modulation, clinical activity and supportive safety. The KT-621 BROADEN2 Phase 2b AD trial is ongoing with data expected by mid-2027, and the BREADTH Phase 2b asthma trial is planned to start in 1Q 2026. The company intends these studies to enable dose selection for parallel Phase 3 registration studies across Type 2 indications.
Kymera Therapeutics (NASDAQ: KYMR) priced an upsized underwritten public offering of 7,000,000 shares at $86.00 per share, raising approximately $602.0 million in gross proceeds; underwriters have a 30‑day option to buy up to an additional 1,050,000 shares at the offering price, less discounts and commissions.
The offering is expected to close on December 11, 2025, subject to customary conditions. Net proceeds are intended to fund advancement of preclinical and clinical degrader programs and for working capital and general corporate purposes. The offering is made from an effective Form S-3 shelf registration filed October 31, 2024.
Kymera Therapeutics (NASDAQ: KYMR) commenced a proposed underwritten public offering of $500.0 million of common stock, with a 30-day underwriter option to purchase up to an additional $75.0 million.
The offering is subject to market and other conditions and may not be completed as proposed. Kymera intends to use net proceeds to advance its preclinical and clinical degrader programs and for working capital and general corporate purposes. The securities are offered under an effective Form S-3 shelf registration (No. 333-282912).
Kymera Therapeutics (NASDAQ: KYMR) reported positive Phase 1b BroADen results for KT-621, an oral STAT6 degrader, in 22 moderate‑to‑severe atopic dermatitis patients dosed for 28 days.
Key data: median STAT6 degradation of 98% in blood and 94% in skin; mean EASI reduction of 63%; median TARC reduction of 74% in patients with baseline TARC comparable to dupilumab studies; FeNO reductions up to 56% in patients with asthma. Safety: no serious adverse events, no treatment‑related TEAEs, and no conjunctivitis reported. BROADEN2 Phase 2b in AD is ongoing with data expected by mid‑2027; BREADTH Phase 2b in asthma planned to start 1Q26.
Kymera Therapeutics (NASDAQ: KYMR) will announce topline results from the BroADen Phase 1b trial of KT-621, an oral STAT6 degrader for moderate to severe atopic dermatitis, on Monday, December 8, 2025.
A press release will be issued at 7:00 a.m. ET, followed by a video conference call and webcast at 8:00 a.m. ET. A replay and presentation will be available after the event. Investors can register via the company website at www.kymeratx.com under News and Events.
Kymera Therapeutics (NASDAQ: KYMR) announced dosing has begun in the BROADEN2 Phase 2b trial of KT-621, an oral STAT6 degrader for moderate to severe atopic dermatitis (AD). The randomized, double-blind, placebo-controlled, dose-ranging study will enroll ~200 patients treated over 16 weeks with three dose arms and a primary endpoint of percent change in EASI score at Week 16.
The company expects BROADEN2 data by mid-2027, completed dosing in the Phase 1b BroADen trial with data due December 2025, and plans to initiate the BREADTH Phase 2b asthma trial in 1Q 2026. Patients may enter a 52-week open-label extension after the trial.
Kymera Therapeutics (NASDAQ: KYMR) will participate in three investor fireside chats in early December 2025: Piper Sandler 37th Annual Healthcare Conference in New York on Dec 2 at 2:30 p.m. ET, Citi 2025 Global Healthcare Conference in Miami on Dec 3 at 11:15 a.m. ET, and Evercore 8th Annual Healthcare Conference in Coral Gables on Dec 4 at 8:45 a.m. ET. Live webcasts and archived replays will be available in the Investors "News and Events" section at www.kymeratx.com.
FAQ
What is the current stock price of Kymera Therapeutics (KYMR)?
What is the market cap of Kymera Therapeutics (KYMR)?
